Lake County, Illinois-based Abbott Laboratories (ABT) discovers, develops, manufactures, and sells health care products worldwide. The company has a market cap of $181.2 billion and operates through Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices segments. Abbott is expected to release its Q1 2026 earnings soon. Ahead of the event, analysts expect the company’s EPS to be $1.15 on a diluted basis, up 5.5% from $1.09 in the year-ago quarter. The company h ...

Sanara MedTech Inc. (SMTI) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to a loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -63.64%. A quarter ago, it was expected that this company would post a loss of $0.24 per share when it actually produced earnings of $0.09, delivering a surprise of +137.5%.Over the last four quarters, the compan ...

Core Insights - The company reported a 2% decline in CORE organic net sales and a $4 million decrease in CORE operating income for the fourth quarter, with CORE EPS at $0.76, down $0.02 year over year [1] - For the full year 2025, all-in operating income grew by 2% and EPS increased by 7% to $2.75, while on a CORE basis, operating income rose by 7% and CORE EPS increased by 14% [1][4] Financial Performance - Management presented results through two lenses: "all-in" (historical operations) and "CORE Perrigo," which excludes infant formula and announced divestitures [2] - The company reported a non-cash $1.3 billion goodwill impairment in 2025, which does not affect cash flow, but is expected to create a $0.60 EPS headwind in 2026 [6][8] - The company ended 2025 with $532 million in cash and generated fourth-quarter operating cash flow of $175 million, totaling $239 million for the full year [20] Strategic Initiatives - The CEO highlighted the "Three-S plan" aimed at simplifying, streamlining, and strengthening the business, with evidence of market share gains and over $100 million in new U.S. store-brand distribution [3][7] - A two-year program targeting annualized pre-tax savings of $80–$100 million was launched, involving a workforce reduction of approximately 7% [5][15] - The company is pursuing a sale of its dermacosmetics business and conducting a strategic review of its infant formula segment to reduce debt and improve margins [5][21] Market Trends and Outlook - The company gained market share across most U.S. OTC categories, reversing years of decline, and noted positive momentum in Europe despite a soft market environment [9] - Looking ahead, management anticipates a difficult start to 2026 for category consumption, with U.S. OTC dollar sales down 5.1% over the last 13 weeks compared to the previous year [10] - Management expects low- to mid-single-digit revenue growth in infant formula in 2026, which is anticipated to help deplete higher inventory levels [22] Future Guidance - For 2026, management guided CORE EPS to be in the range of $2.25 to $2.55, with all-in EPS expected to be between $2.00 and $2.30 [19] - The company described 2026 as a "transition year," with an unfavorable EPS impact of approximately $0.60 due to manufacturing under-absorption [14] - Management reiterated capital allocation priorities of investing in the business, reducing debt, and returning value through dividends, with expectations of achieving net leverage below 3x in the next two to three years [21]

Core Insights - The company attributes its 2025 progress to the 'Three-S' strategy (Simplify, Streamline, Strengthen), which has stabilized the store brand business and improved infant formula service levels above 90% [1] - Performance was driven by significant market share gains in U.S. OTC and European brands, despite a soft market characterized by reduced consumer consumption and a shift to smaller units [1] - The company secured over $100 million in new distribution and competitive takeaways, marking a reversal of years of share decline [1] - Operational results benefited from $320 million in advantages from Project Energize and supply chain reinvention, which helped offset gross profit flow-through headwinds [1] - Management is focusing on 'CORE Perrigo' by divesting non-core assets like Dermacosmetics to concentrate on high-scale consumer health categories [1] - The current market weakness is viewed as 90% transitory, attributed to a lack of historical price increases and a weak cough and cold season rather than structural shifts [1]

Group 1 - The core viewpoint of the article highlights that while like-for-like sales increased by 4.7%, the food company is facing challenges due to a series of infant formula recalls [1] Group 2 - The increase in like-for-like sales indicates a positive trend in consumer demand for the company's products [1] - The recalls of infant formula have negatively impacted the overall perception of the company's latest results, overshadowing the sales growth [1]

Core Viewpoint - Traces of a toxin that can cause nausea and vomiting were detected in two types of infant formula recalled by Danone, as reported by Swiss authorities [1] Group 1 - The infant formula in question was recalled earlier this month by Danone [1] - The toxin found is associated with adverse health effects, specifically nausea and vomiting [1]

Core Viewpoint - Danone is recalling over 120 batches of infant formula in Austria due to potential contamination with the toxin cereulide [1] Company Summary - The recall involves more than 120 batches of infant formula [1] - The reason for the recall is the possible contamination with the toxin cereulide [1] Industry Summary - The incident highlights potential safety concerns in the infant formula sector [1] - Such recalls can impact consumer trust and regulatory scrutiny within the food industry [1]

Infant formula recall is hitting the billionaire clan behind the French firm Lactalis, the world's biggest dairy company https://t.co/lOBBgtj2xY ...

Core Viewpoint - Abbott Laboratories has experienced significant stock underperformance compared to the broader market and key sector indices, raising concerns about its growth outlook and performance in critical segments [2][3][6]. Company Overview - Abbott Laboratories, with a market cap of $189.6 billion, operates globally in healthcare, focusing on pharmaceuticals, diagnostics, nutrition, and medical devices [1]. Stock Performance - Over the past 52 weeks, Abbott's stock has decreased by 15.1%, while the S&P 500 Index has gained 15.4% [2]. - Year-to-date, Abbott's stock has declined nearly 13%, contrasting with a 1.1% rise in the S&P 500 [2]. Segment Performance - In Q4 2025, Abbott reported revenue of $11.46 billion, missing Wall Street estimates, with adjusted EPS of $1.50 meeting expectations [6]. - Key segments showed weak performance: Nutrition sales fell by 8.9% reported (9.1% organic), and Diagnostics declined by 2.5% reported, attributed to lower volumes and reduced COVID-19 testing demand [6]. Growth Outlook - Abbott's organic sales growth outlook for 2026 is projected at 6.5% - 7.5%, which is below prior consensus expectations, contributing to investor concerns [6]. - For the fiscal year ending December 2026, analysts expect adjusted EPS to grow by 10.3% year-over-year to $5.68 [7]. Analyst Ratings - Among 28 analysts covering Abbott, the consensus rating is a "Strong Buy," with 20 "Strong Buy" ratings, two "Moderate Buys," and six "Holds" [7]. - Wells Fargo analyst lowered Abbott's price target to $122 while maintaining an "Overweight" rating, with a mean price target of $134.38 indicating a 23.3% premium to the current price [8].

Core Viewpoint - Danone is proactively recalling specific batches of infant formula products in response to evolving food safety guidance from local authorities, emphasizing its commitment to food safety and quality assurance [1][2]. Group 1: Company Actions - Danone is withdrawing a limited number of specific batches of infant formula products from targeted markets to comply with the latest food safety guidance [2]. - The company reassures parents and healthcare professionals about the safety and quality of its infant formula products [2]. Group 2: Company Overview - Danone is a leading global food and beverage company focused on health-oriented categories, including Essential Dairy & Plant-Based products, Waters, and Specialized Nutrition [4]. - In 2024, Danone generated €27.4 billion in sales and operates in over 120 markets with a workforce of more than 90,000 employees [4]. - The company has a diverse portfolio of international and regional brands, including Actimel, Activia, and evian, and is committed to sustainability and health through its Renew strategy [4].